Emergent BioSolutions Closes On Its Acquisition Of Healthcare Protective Products Division From Bracco Diagnostics Inc.

Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has closed on its acquisition of Bracco Diagnostics Inc.’s Healthcare Protective Products Division. This acquisition, which includes the RSDL ® (decontamination lotion) product that is cleared for marketing by the U.S. Food and Drug Administration (FDA) for removal or neutralization of chemical warfare agents from the skin, diversifies and broadens Emergent’s biodefense franchise into the chemical countermeasure market.

“As a result of this transaction closing, Emergent is focused on the uninterrupted supply of RSDL product to customers and on the seamless integration of the new Healthcare Protective Products Group (HPPG) into our biodefense division,” said Adam Havey, EVP and president of Emergent’s biodefense division. “This news, which comes on the heels of other positive developments in our biodefense division, including receiving BioThrax ® (Anthrax Vaccine Adsorbed) market authorization in Germany as well as reporting positive data from our pivotal study supporting licensure of a post-exposure prophylaxis indication for BioThrax, reinforces Emergent’s leadership position in the biodefense arena.”

The Canadian Department of National Defence and the U.S. Department of the Army have both played a central role in the development and licensing of RSDL, which is also cleared for sale by Health Canada, the U.K. Medicines and Healthcare Products Regulatory Agency, and Australia’s Therapeutics Goods Administration.

The closing on this acquisition contemplates that certain additional assets will be transferred to the company by year end. The company will discuss the impact of this acquisition to Emergent’s anticipated revenue and net income for full year 2013 during the company’s 2Q 2013 financial results call scheduled for August 5, 2013.

About Emergent BioSolutions

Emergent BioSolutions is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding the potential opportunities and financial impact of the transaction, and our financial guidance, and any other statements containing the words “believes”, “expects”, “anticipates”, “intends”, “plans”, “estimates” and similar expressions, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.

If you liked this article you might like

Biotech movers: Ionis Drops After GSK Bows Out of Partnership

Emergent BioSolutions (EBS) Highlighted As Weak On High Volume

New Lifetime High For Emergent BioSolutions (EBS)

New Lifetime High Reached By Emergent BioSolutions (EBS)

New Lifetime High Reached: Emergent BioSolutions (EBS)